Loading…
Impact of intravenous infusion time on AAV8 vector pharmacokinetics, safety, and liver transduction in cynomolgus macaques
Systemically delivered adeno-associated viral (AAV) vectors are now in early-phase clinical trials for a variety of diseases. While there is a general consensus on inclusion and exclusion criteria for each of these trials, the conditions under which vectors are infused vary significantly. In this st...
Saved in:
Published in: | Molecular therapy. Methods & clinical development 2016-01, Vol.3 (C), p.16079-16079, Article 16079 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c503t-5fd49cdda542de34f6267fc0584c4358c603ca7b49ee22c11c4f710fc23b20ef3 |
---|---|
cites | cdi_FETCH-LOGICAL-c503t-5fd49cdda542de34f6267fc0584c4358c603ca7b49ee22c11c4f710fc23b20ef3 |
container_end_page | 16079 |
container_issue | C |
container_start_page | 16079 |
container_title | Molecular therapy. Methods & clinical development |
container_volume | 3 |
creator | Greig, Jenny A Nordin, Jayme Ml Bote, Erin Makaron, Leah Garnett, Mason E Kattenhorn, Lisa M Bell, Peter Goode, Tamara Wilson, James M |
description | Systemically delivered adeno-associated viral (AAV) vectors are now in early-phase clinical trials for a variety of diseases. While there is a general consensus on inclusion and exclusion criteria for each of these trials, the conditions under which vectors are infused vary significantly. In this study, we evaluated the impact of intravenous infusion rate of AAV8 vector in cynomolgus macaques on transgene expression, vector clearance from the circulation, and potential activation of the innate immune system. The dose of AAV8 vector in terms of genome copies per kilogram body weight and its concentration were fixed, while the rate of infusion varied to deliver the entire dose over different time periods, including 1, 10, or 90 minutes. Analyses during the in-life phase of the experiment included sequential evaluation of whole blood for vector genomes and appearance of proinflammatory cytokines. Liver tissues were analyzed at the time of necropsy for enhanced green fluorescent protein (eGFP) expression and vector genomes. The data were remarkable with a relative absence of any statistically significant effect of infusion time on vector transduction, safety, and clearance. However, some interesting and unexpected trends did emerge. |
doi_str_mv | 10.1038/mtm.2016.79 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_1257334449464218b79428fe5b2e4286</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_1257334449464218b79428fe5b2e4286</doaj_id><sourcerecordid>2307590046</sourcerecordid><originalsourceid>FETCH-LOGICAL-c503t-5fd49cdda542de34f6267fc0584c4358c603ca7b49ee22c11c4f710fc23b20ef3</originalsourceid><addsrcrecordid>eNp9ks1rFDEYxoMotqw9eZeAF8Hums9J5iIsxdaFghf1GjKZZJt1JlmTzML615txa2k9mMv7kjz5kffJA8BrjFYYUflhLOOKINysRPsMnBNK2iXiCD9_1J-Bi5x3qK5WIMrbl-CMiJZSisQ5-LUZ99oUGB30oSR9sCFOufZuyj4GWPxoYa3r9XcJD9aUmOD-TqdRm_jDB1u8yZcwa2fL8RLq0MPBH2yCFRVyP5kyQ3yA5hjiGIdtZder-udk8yvwwukh24v7ugDfrj99vfq8vP1ys7la3y4NR7QsuetZa_pec0Z6S5lrSCOcQVwywyiXpkHUaNGx1lpCDMaGOYGRM4R2BFlHF2Bz4vZR79Q--VGno4raqz8bMW2VTnWOwSpMuKCUMdayhhEsO9EyIp3lHbG1aSrr44m1n7rR9sbOng1PoE9Pgr9T23hQHDPCkayAd_eAFGcTihp9NnYYdLDVeIUlE7J-jqRV-vYf6S5OKVSrFKl_x1uEWPM_VWU1jAqBSVW9P6lMijkn6x6ejJGag6RqkNQcJFWjsQBvHk_5oP0bG_obYGbDsQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1846437712</pqid></control><display><type>article</type><title>Impact of intravenous infusion time on AAV8 vector pharmacokinetics, safety, and liver transduction in cynomolgus macaques</title><source>PubMed (Medline)</source><source>Publicly Available Content Database</source><source>ScienceDirect Journals</source><creator>Greig, Jenny A ; Nordin, Jayme Ml ; Bote, Erin ; Makaron, Leah ; Garnett, Mason E ; Kattenhorn, Lisa M ; Bell, Peter ; Goode, Tamara ; Wilson, James M</creator><creatorcontrib>Greig, Jenny A ; Nordin, Jayme Ml ; Bote, Erin ; Makaron, Leah ; Garnett, Mason E ; Kattenhorn, Lisa M ; Bell, Peter ; Goode, Tamara ; Wilson, James M</creatorcontrib><description>Systemically delivered adeno-associated viral (AAV) vectors are now in early-phase clinical trials for a variety of diseases. While there is a general consensus on inclusion and exclusion criteria for each of these trials, the conditions under which vectors are infused vary significantly. In this study, we evaluated the impact of intravenous infusion rate of AAV8 vector in cynomolgus macaques on transgene expression, vector clearance from the circulation, and potential activation of the innate immune system. The dose of AAV8 vector in terms of genome copies per kilogram body weight and its concentration were fixed, while the rate of infusion varied to deliver the entire dose over different time periods, including 1, 10, or 90 minutes. Analyses during the in-life phase of the experiment included sequential evaluation of whole blood for vector genomes and appearance of proinflammatory cytokines. Liver tissues were analyzed at the time of necropsy for enhanced green fluorescent protein (eGFP) expression and vector genomes. The data were remarkable with a relative absence of any statistically significant effect of infusion time on vector transduction, safety, and clearance. However, some interesting and unexpected trends did emerge.</description><identifier>ISSN: 2329-0501</identifier><identifier>EISSN: 2329-0501</identifier><identifier>DOI: 10.1038/mtm.2016.79</identifier><identifier>PMID: 27933307</identifier><language>eng</language><publisher>United States: Elsevier Limited</publisher><subject>Animals ; Body weight ; Clinical trials ; Cytokines ; Cytotoxicity ; Deoxyribonucleic acid ; DNA ; Efficiency ; Enzymes ; Gene therapy ; Genomes ; Green fluorescent protein ; Immune clearance ; Immune system ; Immunology ; Inflammation ; Innate immunity ; Intravenous administration ; Liver ; Necropsy ; Pharmacokinetics ; Statistical analysis ; Vectors (Biology) ; Veins & arteries</subject><ispartof>Molecular therapy. Methods & clinical development, 2016-01, Vol.3 (C), p.16079-16079, Article 16079</ispartof><rights>Copyright Nature Publishing Group Dec 2016</rights><rights>2016. Official journal of the American Society of Gene & Cell Therapy</rights><rights>Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy 2016 Official journal of the American Society of Gene & Cell Therapy</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c503t-5fd49cdda542de34f6267fc0584c4358c603ca7b49ee22c11c4f710fc23b20ef3</citedby><cites>FETCH-LOGICAL-c503t-5fd49cdda542de34f6267fc0584c4358c603ca7b49ee22c11c4f710fc23b20ef3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5142508/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2307590046?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25752,27923,27924,37011,37012,44589,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27933307$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Greig, Jenny A</creatorcontrib><creatorcontrib>Nordin, Jayme Ml</creatorcontrib><creatorcontrib>Bote, Erin</creatorcontrib><creatorcontrib>Makaron, Leah</creatorcontrib><creatorcontrib>Garnett, Mason E</creatorcontrib><creatorcontrib>Kattenhorn, Lisa M</creatorcontrib><creatorcontrib>Bell, Peter</creatorcontrib><creatorcontrib>Goode, Tamara</creatorcontrib><creatorcontrib>Wilson, James M</creatorcontrib><title>Impact of intravenous infusion time on AAV8 vector pharmacokinetics, safety, and liver transduction in cynomolgus macaques</title><title>Molecular therapy. Methods & clinical development</title><addtitle>Mol Ther Methods Clin Dev</addtitle><description>Systemically delivered adeno-associated viral (AAV) vectors are now in early-phase clinical trials for a variety of diseases. While there is a general consensus on inclusion and exclusion criteria for each of these trials, the conditions under which vectors are infused vary significantly. In this study, we evaluated the impact of intravenous infusion rate of AAV8 vector in cynomolgus macaques on transgene expression, vector clearance from the circulation, and potential activation of the innate immune system. The dose of AAV8 vector in terms of genome copies per kilogram body weight and its concentration were fixed, while the rate of infusion varied to deliver the entire dose over different time periods, including 1, 10, or 90 minutes. Analyses during the in-life phase of the experiment included sequential evaluation of whole blood for vector genomes and appearance of proinflammatory cytokines. Liver tissues were analyzed at the time of necropsy for enhanced green fluorescent protein (eGFP) expression and vector genomes. The data were remarkable with a relative absence of any statistically significant effect of infusion time on vector transduction, safety, and clearance. However, some interesting and unexpected trends did emerge.</description><subject>Animals</subject><subject>Body weight</subject><subject>Clinical trials</subject><subject>Cytokines</subject><subject>Cytotoxicity</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>Efficiency</subject><subject>Enzymes</subject><subject>Gene therapy</subject><subject>Genomes</subject><subject>Green fluorescent protein</subject><subject>Immune clearance</subject><subject>Immune system</subject><subject>Immunology</subject><subject>Inflammation</subject><subject>Innate immunity</subject><subject>Intravenous administration</subject><subject>Liver</subject><subject>Necropsy</subject><subject>Pharmacokinetics</subject><subject>Statistical analysis</subject><subject>Vectors (Biology)</subject><subject>Veins & arteries</subject><issn>2329-0501</issn><issn>2329-0501</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9ks1rFDEYxoMotqw9eZeAF8Hums9J5iIsxdaFghf1GjKZZJt1JlmTzML615txa2k9mMv7kjz5kffJA8BrjFYYUflhLOOKINysRPsMnBNK2iXiCD9_1J-Bi5x3qK5WIMrbl-CMiJZSisQ5-LUZ99oUGB30oSR9sCFOufZuyj4GWPxoYa3r9XcJD9aUmOD-TqdRm_jDB1u8yZcwa2fL8RLq0MPBH2yCFRVyP5kyQ3yA5hjiGIdtZder-udk8yvwwukh24v7ugDfrj99vfq8vP1ys7la3y4NR7QsuetZa_pec0Z6S5lrSCOcQVwywyiXpkHUaNGx1lpCDMaGOYGRM4R2BFlHF2Bz4vZR79Q--VGno4raqz8bMW2VTnWOwSpMuKCUMdayhhEsO9EyIp3lHbG1aSrr44m1n7rR9sbOng1PoE9Pgr9T23hQHDPCkayAd_eAFGcTihp9NnYYdLDVeIUlE7J-jqRV-vYf6S5OKVSrFKl_x1uEWPM_VWU1jAqBSVW9P6lMijkn6x6ejJGag6RqkNQcJFWjsQBvHk_5oP0bG_obYGbDsQ</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Greig, Jenny A</creator><creator>Nordin, Jayme Ml</creator><creator>Bote, Erin</creator><creator>Makaron, Leah</creator><creator>Garnett, Mason E</creator><creator>Kattenhorn, Lisa M</creator><creator>Bell, Peter</creator><creator>Goode, Tamara</creator><creator>Wilson, James M</creator><general>Elsevier Limited</general><general>Nature Publishing Group</general><general>Elsevier</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20160101</creationdate><title>Impact of intravenous infusion time on AAV8 vector pharmacokinetics, safety, and liver transduction in cynomolgus macaques</title><author>Greig, Jenny A ; Nordin, Jayme Ml ; Bote, Erin ; Makaron, Leah ; Garnett, Mason E ; Kattenhorn, Lisa M ; Bell, Peter ; Goode, Tamara ; Wilson, James M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c503t-5fd49cdda542de34f6267fc0584c4358c603ca7b49ee22c11c4f710fc23b20ef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animals</topic><topic>Body weight</topic><topic>Clinical trials</topic><topic>Cytokines</topic><topic>Cytotoxicity</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>Efficiency</topic><topic>Enzymes</topic><topic>Gene therapy</topic><topic>Genomes</topic><topic>Green fluorescent protein</topic><topic>Immune clearance</topic><topic>Immune system</topic><topic>Immunology</topic><topic>Inflammation</topic><topic>Innate immunity</topic><topic>Intravenous administration</topic><topic>Liver</topic><topic>Necropsy</topic><topic>Pharmacokinetics</topic><topic>Statistical analysis</topic><topic>Vectors (Biology)</topic><topic>Veins & arteries</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Greig, Jenny A</creatorcontrib><creatorcontrib>Nordin, Jayme Ml</creatorcontrib><creatorcontrib>Bote, Erin</creatorcontrib><creatorcontrib>Makaron, Leah</creatorcontrib><creatorcontrib>Garnett, Mason E</creatorcontrib><creatorcontrib>Kattenhorn, Lisa M</creatorcontrib><creatorcontrib>Bell, Peter</creatorcontrib><creatorcontrib>Goode, Tamara</creatorcontrib><creatorcontrib>Wilson, James M</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Molecular therapy. Methods & clinical development</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Greig, Jenny A</au><au>Nordin, Jayme Ml</au><au>Bote, Erin</au><au>Makaron, Leah</au><au>Garnett, Mason E</au><au>Kattenhorn, Lisa M</au><au>Bell, Peter</au><au>Goode, Tamara</au><au>Wilson, James M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of intravenous infusion time on AAV8 vector pharmacokinetics, safety, and liver transduction in cynomolgus macaques</atitle><jtitle>Molecular therapy. Methods & clinical development</jtitle><addtitle>Mol Ther Methods Clin Dev</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>3</volume><issue>C</issue><spage>16079</spage><epage>16079</epage><pages>16079-16079</pages><artnum>16079</artnum><issn>2329-0501</issn><eissn>2329-0501</eissn><abstract>Systemically delivered adeno-associated viral (AAV) vectors are now in early-phase clinical trials for a variety of diseases. While there is a general consensus on inclusion and exclusion criteria for each of these trials, the conditions under which vectors are infused vary significantly. In this study, we evaluated the impact of intravenous infusion rate of AAV8 vector in cynomolgus macaques on transgene expression, vector clearance from the circulation, and potential activation of the innate immune system. The dose of AAV8 vector in terms of genome copies per kilogram body weight and its concentration were fixed, while the rate of infusion varied to deliver the entire dose over different time periods, including 1, 10, or 90 minutes. Analyses during the in-life phase of the experiment included sequential evaluation of whole blood for vector genomes and appearance of proinflammatory cytokines. Liver tissues were analyzed at the time of necropsy for enhanced green fluorescent protein (eGFP) expression and vector genomes. The data were remarkable with a relative absence of any statistically significant effect of infusion time on vector transduction, safety, and clearance. However, some interesting and unexpected trends did emerge.</abstract><cop>United States</cop><pub>Elsevier Limited</pub><pmid>27933307</pmid><doi>10.1038/mtm.2016.79</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2329-0501 |
ispartof | Molecular therapy. Methods & clinical development, 2016-01, Vol.3 (C), p.16079-16079, Article 16079 |
issn | 2329-0501 2329-0501 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_1257334449464218b79428fe5b2e4286 |
source | PubMed (Medline); Publicly Available Content Database; ScienceDirect Journals |
subjects | Animals Body weight Clinical trials Cytokines Cytotoxicity Deoxyribonucleic acid DNA Efficiency Enzymes Gene therapy Genomes Green fluorescent protein Immune clearance Immune system Immunology Inflammation Innate immunity Intravenous administration Liver Necropsy Pharmacokinetics Statistical analysis Vectors (Biology) Veins & arteries |
title | Impact of intravenous infusion time on AAV8 vector pharmacokinetics, safety, and liver transduction in cynomolgus macaques |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T22%3A46%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20intravenous%20infusion%20time%20on%20AAV8%20vector%20pharmacokinetics,%20safety,%20and%20liver%20transduction%20in%20cynomolgus%20macaques&rft.jtitle=Molecular%20therapy.%20Methods%20&%20clinical%20development&rft.au=Greig,%20Jenny%20A&rft.date=2016-01-01&rft.volume=3&rft.issue=C&rft.spage=16079&rft.epage=16079&rft.pages=16079-16079&rft.artnum=16079&rft.issn=2329-0501&rft.eissn=2329-0501&rft_id=info:doi/10.1038/mtm.2016.79&rft_dat=%3Cproquest_doaj_%3E2307590046%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c503t-5fd49cdda542de34f6267fc0584c4358c603ca7b49ee22c11c4f710fc23b20ef3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1846437712&rft_id=info:pmid/27933307&rfr_iscdi=true |